The head of the Federal Medical and Biological Agency of Russia (FMBA), former Minister of Health Veronika Skvortsova, announced that the Russian anti-cancer vaccine has passed preclinical trials, which means it is ready for use and the agency is waiting for the Ministry of Health to grant a license for clinical use. FMBA submitted an application to the Ministry of Health at the end of last summer.
According to a VNA correspondent in Moscow, Ms. Skvortsova said that studies have proven the safety of the vaccine, such as repeated use, and high efficiency in terms of reducing the size and slowing the growth of tumors significantly (up to 60 - 80%). In addition, studies have shown an increase in survival rates, which is also a very important factor.
According to Ms. Skvortsova, the vaccine will be used initially for colorectal cancer. In parallel, FMBA is also completing the development of a vaccine against glioblastoma, one of the most malignant tumors, with barrier tumors located behind the blood-brain barrier in the brain structure, and special types of melanoma./.
Binh Nguyen